Related Experiment Videos

Are racial differences in antihypertensive responsiveness reflected in usage after stroke?

Bruce Ovbiagele1, Nancy K Hills, Jeffrey L Saver

  • 1Stroke Center and Department of Neurology, University of California at Los Angeles Medical Center, Los Angeles, California, USA.

Insights

Black patients hospitalized for ischemic stroke received similar antihypertensive prescriptions compared to other races. This study found no differences in discharge medication patterns, despite known variations in drug response.

Area of Science:

  • Clinical Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Differential antihypertensive drug responses are documented in Black populations.
  • Understanding prescription patterns is crucial for optimizing stroke care.
  • Ischemic cerebrovascular events require effective post-hospitalization management.

Purpose of the Study:

  • To investigate if racial disparities in antihypertensive effectiveness are reflected in discharge medication practices.
  • To compare antihypertensive prescription rates in Black patients versus other races following ischemic stroke hospitalization.

Main Methods:

  • Analysis of discharge antihypertensive medication use from the California Acute Stroke Prototype Registry.
  • Comparison of prescription rates between Black patients and all other races combined.
  • Use of generalized estimating equations to identify factors associated with medication receipt.

Main Results:

  • No significant differences in overall antihypertensive use were observed between Black patients (74%) and other races (69%).
  • Specific categories of antihypertensives showed no significant disparity in prescription rates.
  • A non-significant trend indicated more frequent diuretic use in Black patients (P = .12).

Conclusions:

  • Discharge antihypertensive prescription patterns did not differ between Black patients and other races hospitalized with ischemic stroke or transient ischemic attack.
  • Current prescribing practices may not account for known differential responses to antihypertensives in Black individuals.
  • Further research is needed to align treatment strategies with observed pharmacological differences.
Abstract

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...